Comparing Injectable Platelet-Rich Fibrin and Intradermal Tranexamic Acid for Treating Female Facial Melasma in Adults Aged 18 to 50

What this Trial Is About

Melasma is a common chronic skin condition causing brown to gray-brown patches, primarily on the face, especially in adult women with certain skin types. This research compares two treatments for facial melasma injectable platelet-rich fibrin i-PRF, a platelet concentrate from the patients own blood, and intradermal tranexamic acid TA, a drug that may reduce pigmentation. The study aims to assess which treatment is safer and more effective for improving melasma. Adult female patients with mild to moderate symmetrical facial melasma will participate. Each participants face will be split one side will receive i-PRF injections prepared from their blood, and the other side will receive intradermal tranexamic acid injections. Both treatments will be given in five sessions spaced two weeks apart, alongside instructions to use sunscreen and avoid other facial treatments. Participants will be evaluated before treatment and 90 days later using various measures such as the modified Melasma Area and Severity Index mMASI, skin imaging with the Antera 3D camera, physician assessments, patient satisfaction, and quality of life questionnaires. Safety will be monitored by recording any side effects like pain, redness, swelling, or bruising. This study is designed to provide detailed comparisons of efficacy and safety between these two treatments.

Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma